Aung Htun M, Thida Aye M, Fils-Aime Melissa, Thwin Malar
Department of Medicine, Interfaith Medical Center, Brooklyn, USA.
Department of Medicine, Woodhull Medical and Mental Health Center, Brooklyn, USA.
Cureus. 2021 Oct 5;13(10):e18496. doi: 10.7759/cureus.18496. eCollection 2021 Oct.
A 58-year-old male with a history of hypertension, dyslipidemia, osteoarthritis of both knees, and morbid obesity presented to the emergency department for opioid detoxification. He complained of generalized soreness, anxiety, and difficulty sleeping but denied signs and symptoms suggestive of coronavirus disease 2019 (COVID-19) infection. His COVID-19 polymerase chain reaction (PCR) result came back positive, and his D-dimer level was 5373 ng/mL. A computed tomography pulmonary angiogram showed a moderate burden of bilateral acute pulmonary emboli. He was managed with enoxaparin sodium subcutaneous therapeutic dose for three days, followed by oral apixaban 10 mg twice a day for seven days and then 5 mg twice a day for six months. To date, the rate of venous thromboembolism (VTE) in nonhospitalized patients with COVID-19 has not been reported, and current guidelines do not recommend thromboprophylaxis for these patients.
一名58岁男性，有高血压、血脂异常、双膝骨关节炎和病态肥胖病史，因阿片类药物脱毒入住急诊科。他主诉全身酸痛、焦虑和睡眠困难，但否认有提示2019冠状病毒病（COVID-19）感染的体征和症状。他的COVID-19聚合酶链反应（PCR）结果呈阳性，D-二聚体水平为5373 ng/mL。计算机断层扫描肺血管造影显示双侧急性肺栓塞负担中等。他接受了三天皮下治疗剂量的依诺肝素钠治疗，随后口服阿哌沙班，先10 mg每日两次，共七天，然后5 mg每日两次，持续六个月。迄今为止，尚未报告非住院COVID-19患者的静脉血栓栓塞（VTE）发生率，目前的指南也不建议对这些患者进行血栓预防。
